Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...

Terns Pharmaceuticals recently posted positive results from a clinical trial involving a weight-loss pill. The results looked ...

We came across a bullish thesis on Schrödinger, Inc. (SDGR) on Value Degen’s Substack by Unemployed Value Degen. In this ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 589.06% and ...

The move significantly expands the supply of Zepbound in response to high demand and offers a more affordable option.

INDIANAPOLIS–The U.S. Food and Drug Administration has approved Eli Lilly’s new treatment for moderate to severe eczema. It’s ...

Aronne, MD, of Weill Cornell Medicine in New York City, made a compelling case that the next generation of obesity ...

Eli Lilly & Co. closed $71.28 below its 52-week high ($972.53), which the company achieved on August 22nd.

Sept 5 (Reuters) - U.S. drugmaker Eli Lilly (LLY.N), opens new tab has signed a research deal with privately held AI-focused firm Genetic Leap to develop genetic medicines, the latter said on Thursday ...

The investments are part of Lilly's ongoing commitment to expand production, especially for its top-selling diabetes and obesity drugs, Mounjaro and Zepbound, respectively. The company has committed ...

Eli Lilly is acquisitive, too, and just purchased a company called Morphic Holding. The acquisition expands the healthcare giant's immunology drug franchise and specifically brings new potential ...

Eli Lilly has entered into a research deal with artificial intelligence-focused firm Genetic Leap for up to $409 million to develop genetic medicines, the latter said on Thursday. (Reporting by Mariam ...